Lucira Health

medical devices

About

Lucira Health is a medical technology company that develops and commercializes innovative diagnostic test kits for infectious diseases. Founded in 2013 and formerly known as Diassess, Inc., the company gained recognition for creating the first FDA-authorized at-home molecular COVID-19 test. Lucira Health has since expanded its offerings to include a combined COVID-19 and Flu A/B home test. In 2021, the company went public on NASDAQ under the ticker LHDX and was acquired by Pfizer Inc. in 2023. The flagship product, branded as LUCIRA® by Pfizer COVID-19 & Flu Home Test, is the first molecular test authorized for emergency use by the FDA that can detect and differentiate between COVID-19, influenza A, and influenza B viruses at home. This test provides results in 30 minutes or less and is designed for easy use with just three steps: swab, stir, and detect. Lucira Health aims to empower consumers and healthcare providers with rapid testing solutions that facilitate timely care decisions. The company is headquartered in Emeryville, California, where it focuses on research, development, and commercial strategy.

Technologies

CloudFlare CDN CloudFlare Hosting Atlassian Cloud React Redux Remote

Keywords

mobile medical devices diagnostics information technology medical health care biotechnology: electromedical & electrotherapeutic apparatus medical equipment manufacturing medical equipment and supplies manufacturing covid-19 and flu testing retail test kit manufacturing smartphone-compatible diagnostics viral rna amplification rapid infectious disease testing disposable test device flu strain detection disposable diagnostic device rt-lamp amplification molecular diagnostic b2c patient care public health testing lab-in-a-palm device molecular testing platform decentralized diagnostics molecular diagnostics pcr-like technology point-of-care testing diagnostic hardware

Location

Oakland, California, United States, 94608

Related Companies

Companies in the same industry